Il Han Kim

List of Publications by Year
in descending order

77 papers	1,720 citations	331670 21 h-index	315739 38 g-index
80 all docs	80 docs citations	80 times ranked	3004 citing authors

#	Article	IF	Citations
1	Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis. Cancer Research, 2019, 79, 795-806.	0.9	188
2	The role of adjuvant radiotherapy in atypical meningioma. Journal of Neuro-Oncology, 2013, 115, 241-247.	2.9	121
3	Intramedullary spinal cord astrocytoma in adults: postoperative outcome. Journal of Neuro-Oncology, 2001, 52, 85-94.	2.9	105
4	Early adjuvant radiotherapy toward long-term survival and better quality of life for craniopharyngiomasâ€"a study in single institute. Child's Nervous System, 2005, 21, 799-807.	1.1	99
5	Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. Journal of Neuro-Oncology, 2015, 121, 141-150.	2.9	92
6	Prediction of Pseudoprogression versus Progression using Machine Learning Algorithm in Glioblastoma. Scientific Reports, 2018, 8, 12516.	3.3	88
7	Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma. European Radiology, 2018, 28, 4350-4361.	4.5	63
8	Expression level ofhTERTis regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget, 2014, 5, 3399-3407.	1.8	50
9	Adjuvant single-fraction radiotherapy is safe and effective for intractable keloids. Journal of Radiation Research, 2014, 55, 912-916.	1.6	43
10	Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma. Cancer Research and Treatment, 2017, 49, 387-398.	3.0	41
11	Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2015, 17, 810-821.	1.2	38
12	Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2019, 143, 321-328.	2.9	34
13	Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. Radiotherapy and Oncology, 2017, 123, 106-111.	0.6	32
14	Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phaseÂIII trial. Journal of Neuro-Oncology, 2011, 103, 595-602.	2.9	29
15	Treatment of intracranial nongerminomatous malignant germ cell tumor in children: the role of each treatment modality. Child's Nervous System, 1999, 15, 185-191.	1.1	27
16	Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging. European Radiology, 2017, 27, 1176-1185.	4.5	27
17	Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study. European Radiology, 2017, 27, 3156-3166.	4.5	27
18	Texture analysis on the fluence map to evaluate the degree of modulation for volumetric modulated arc therapy. Medical Physics, 2014, 41, 111718.	3.0	26

#	Article	IF	Citations
19	Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Cancer Research and Treatment, 2017, 49, 193-203.	3.0	26
20	Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors. Journal of Korean Medical Science, 2014, 29, 1094.	2.5	22
21	Additional Survival Benefit of Involved-Lesion Radiation Therapy After R-CHOP Chemotherapy in Limited Stage Diffuse Large B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2015, 92, 91-98.	0.8	22
22	Machine Learning Model to Predict Pseudoprogression Versus Progression in Glioblastoma Using MRI: A Multi-Institutional Study (KROG 18-07). Cancers, 2020, 12, 2706.	3.7	21
23	Evaluation of variability in target volume delineation for newly diagnosed glioblastoma: a multi-institutional study from the Korean Radiation Oncology Group. Radiation Oncology, 2016, 10, 137.	2.7	20
24	Differentiation of High-Grade from Low-Grade Astrocytoma: Improvement in Diagnostic Accuracy and Reliability of Pharmacokinetic Parameters from DCE MR Imaging by Using Arterial Input Functions Obtained from DSC MR Imaging. Radiology, 2018, 286, 981-991.	7.3	20
25	Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy. Journal of Neuro-Oncology, 2017, 134, 169-175.	2.9	20
26	Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor. Neuro-Oncology, 2017, 19, 1079-1087.	1.2	19
27	Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study. Radiotherapy and Oncology, 2018, 129, 347-351.	0.6	18
28	Survival gain with re-Op/RT for recurred high-grade gliomas depends upon risk groups. Radiotherapy and Oncology, 2018, 128, 254-259.	0.6	18
29	Upfront chemotherapy followed by response adaptive radiotherapy for intracranial germinoma: Prospective multicenter cohort study. Radiotherapy and Oncology, 2019, 138, 180-186.	0.6	18
30	Texture analysis on the edge-enhanced fluence of VMAT. Radiation Oncology, 2015, 10, 74.	2.7	17
31	Efficacy of adjuvant radiotherapy in the intracranial hemangiopericytoma. Journal of Neuro-Oncology, 2018, 137, 567-573.	2.9	17
32	The Role of Postoperative Radiotherapy in Intracranial Solitary Fibrous Tumor/Hemangiopericytoma: A Multi-institutional Retrospective Study (KROG 18-11). Cancer Research and Treatment, 2022, 54, 65-74.	3.0	17
33	Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging. Korean Journal of Radiology, 2015, 16, 1341.	3.4	16
34	Loss of Pericytes in Radiation Necrosis after Glioblastoma Treatments. Molecular Neurobiology, 2018, 55, 4918-4926.	4.0	16
35	Prognosis Prediction of Measurable Enhancing Lesion after Completion of Standard Concomitant Chemoradiotherapy and Adjuvant Temozolomide in Glioblastoma Patients: Application of Dynamic Susceptibility Contrast Perfusion and Diffusion-Weighted Imaging. PLoS ONE, 2014, 9, e113587.	2.5	15
36	Combined use of susceptibility weighted magnetic resonance imaging sequences and dynamic susceptibility contrast perfusion weighted imaging to improve the accuracy of the differential diagnosis of recurrence and radionecrosis in high-grade glioma patients. Oncotarget, 2017, 8, 20340-20353.	1.8	15

#	Article	IF	Citations
37	Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma. Radiation Oncology Journal, 2020, 38, 35-43.	1.5	15
38	Outcomes of intracranial germinomaâ€”A retrospective multinational Asian study on effect of clinical presentation and differential treatment strategies. Neuro-Oncology, 2022, 24, 1389-1399.	1.2	15
39	Early cognitive function tests predict early progression in glioblastoma. Neuro-Oncology Practice, 2015, 2, 137-143.	1.6	14
40	Validation and optimization of aÂweb-based nomogram for predicting survival of patients with newly diagnosed glioblastoma. Strahlentherapie Und Onkologie, 2020, 196, 58-69.	2.0	14
41	Appraisal of re-irradiation for the recurrent glioblastoma in the era of MGMT promotor methylation. Radiation Oncology Journal, 2019, 37, 1-12.	1.5	14
42	Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection?. Journal of Neuro-Oncology, 2020, 148, 57-65.	2.9	13
43	Role of radiation therapy in primary central nervous system lymphoma. Journal of Neuro-Oncology, 2017, 135, 629-638.	2.9	11
44	Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value. American Journal of Neuroradiology, 2020, 41, 49-56.	2.4	11
45	Immunohistochemical analysis of cyclooxygenaseâ€2 and brain fatty acid binding protein expression in grades <scp>I</scp>â€<scp>II</scp> meningiomas: Correlation with tumor grade and clinical outcome after radiotherapy. Neuropathology, 2014, 34, 446-454.	1.2	10
46	Application of diffusion-weighted imaging and dynamic susceptibility contrast perfusion-weighted imaging for ganglioglioma in adults: Comparison study with oligodendroglioma. Journal of Neuroradiology, 2016, 43, 331-338.	1.1	10
47	Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging. Neuroradiology, 2015, 57, 1111-1120.	2.2	9
48	MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction. PLoS ONE, 2016, 11, e0166096.	2.5	9
49	Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type. Cancer Research and Treatment, 2018, 50, 670-680.	3.0	9
50	Postoperative radiotherapy for WHO grade IIâ€“III intracranial ependymoma in adults: An intergroup collaborative study (KROG 18-06/KNOG 18-01). Radiotherapy and Oncology, 2020, 150, 4-11.	0.6	9
51	MR Imaging Evaluation of Intracerebral Hemorrhages and T2 Hyperintense White Matter Lesions Appearing after Radiation Therapy in Adult Patients with Primary Brain Tumors. PLoS ONE, 2015, 10, e0136795.	2.5	9
52	Sequence-Dependent Radiosensitization of Histone Deacetylase Inhibitors Trichostatin A and SK-7041. Cancer Research and Treatment, 2013, 45, 334-342.	3.0	8
53	Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features. International Journal of Clinical Oncology, 2015, 20, 21-28.	2.2	8
54	Long-Term Outcomes and Sequelae Analysis of Intracranial Germinoma: Need to Reduce the Extended-Field Radiotherapy Volume and Dose to Minimize Late Sequelae. Cancer Research and Treatment, 2021, 53, 983-990.	3.0	8

#	Article	IF	Citations
55	Textural feature calculated from segmental fluences as a modulation index for VMAT. Physica Medica, 2015, 31, 981-990.	0.7	7
56	Leakage correction improves prognosis prediction of dynamic susceptibility contrast perfusion MRI in primary central nervous system lymphoma. Scientific Reports, 2018, 8, 456.	3.3	7
57	Pediatric Spinal Epidural Lymphoma Presenting with Compressive Myelopathy: A Distinct Pattern of Disease Presentation. World Neurosurgery, 2018, 114, e689-e697.	1.3	7
58	Prognostication of anaplastic astrocytoma patients: application of contrast leakage information of dynamic susceptibility contrast-enhanced MRI and dynamic contrast-enhanced MRI. European Radiology, 2020, 30, 2171-2181.	4.5	7
59	Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas. Korean Journal of Radiology, 2021, 22, 233.	3.4	6
60	Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. Cancer Research and Treatment, 2017, 49, 129-140.	3.0	5
61	Design and evaluation of electron beam energy degraders for breast boost irradiation. Radiation Oncology, 2016, 11, 112.	2.7	4
62	Benefit of volumetric-modulated arc therapy over three-dimensional conformal radiotherapy for stage I-II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the stomach: a dosimetric comparison. Radiation Oncology Journal, 2018, 36, 332-340.	1.5	4
63	Recursive partitioning analysis for disease progression in adult intracranial ependymoma patients. Journal of Clinical Neuroscience, 2017, 46, 72-78.	1.5	3
64	A phthalimidoalkanamide derived novel DNMT inhibitor enhanced radiosensitivity of A549 cells by inhibition of homologous recombination of DNA damage. Investigational New Drugs, 2019, 37, 1158-1165.	2.6	3
65	The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma. Journal of Clinical Neuroscience, 2016, 34, 145-150.	1.5	1
66	Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions. American Journal of Neuroradiology, 2019, 40, 2052-2058.	2.4	1
67	In vivoRadiosensitization Effect of HDAC Inhibitor, SK-7041 on RIF-1 Cell Line. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2010, 28, 219.	0.1	1
68	Clinical outcomes and prognostic factors in patients with mycosis fungoides who underwent radiation therapy in a single institution. Radiation Oncology Journal, 2018, 36, 153-162.	1.5	1
69	Does fluid collection impact radiotherapy outcomes after wide excision of lower extremity soft tissue sarcoma?. Japanese Journal of Clinical Oncology, 2018, 48, 153-159.	1.3	0
70	Artifact-free CT images for electron beam therapy using a patient-specific non metallic shield. Physica Medica, 2020, 75, 92-99.	0.7	0
71	Comparative Analysis of Patterns of Care Study of Radiotherapy for Esophageal Cancer among Three Countries: South Korea, Japan and the United States. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2008, 26, 83.	0.1	0
72	A Retrospective Study of the Radiotherapy Care Patterns for Patients with Laryngeal Cancer and Comparison of Different Korean Hospitals Treated from 1998 through 1999. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2009, 27, 201.	0.1	0

#	Article	IF	Citations
73	Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.. Journal of Clinical Oncology, 2013, 31, 2098-2098.	1.6	0
74	Differentiation of True Recurrence from Delayed Radiation Therapy-related Changes in Primary Brain Tumors Using Diffusion-weighted Imaging, Dynamic Susceptibility Contrast Perfusion Imaging, and Susceptibility-weighted Imaging. Journal of the Korean Society of Magnetic Resonance in Medicine, 2014, 18, 120.	0.1	0
75	GCT-02. THE LONG-TERM OUTCOMES AND SEQUELAE ANALYSIS OF INTRACRANIAL GERMINOMA FROM 187 PATIENTS IN THE SINGLE INSTITUTE: NECESSITY FOR THE ADAPTATION OF RADIOTHERAPY DOSE AND VOLUME. Neuro-Oncology, 2020, 22, iii328-iii329.	1.2	0
76	RADT-35. POSTOPERATIVE RADIOTHERAPY FOR WHO GRADE IIâ€“III INTRACRANIAL EPENDYMOMA IN ADULTS: AN INTERGROUP COLLABORATIVE STUDY (KROG 18-06/KNOG 18-01). Neuro-Oncology, 2020, 22, ii189-ii189.	1.2	0
77	Suggestions for Escaping the Dark Ages for Pediatric Diffuse Intrinsic Pontine Glioma Treated with Radiotherapy: Analysis of Prognostic Factors from the National Multicenter Study. Cancer Research and Treatment, 2023, 55, 41-49.	3.0	0